hotspot -WSS

hotspot

author：Wikipedia 2025-10-01 22:16:17 - browse：375

Cambridge: AbbVie — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 — nearly a million dollars more than the company has ever spent in a single quarter. Ruby Wallau for STAT

WASHINGTON — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 alone — more than any other drugmaker spent in the same period, and nearly a million dollars more than the company spent in the same period last year.

AbbVie was the seventh-highest corporate lobbying spender last quarter, ahead of giants like Lockheed Martin, CVS Health, and, AT&T, federal records show.

The number is eye-popping even for the pharmaceutical industry, which is known for its omnipresence on Capitol Hill, and its nearly unlimited lobbying budgets.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： CRISPR technology availability, affordability needs to be expanded

entertainment

WSS

Diabetes management: Digital health tools fall short, study says

Bring on the sabbaticals for nurses

Steward Health Care expansion into Malta flopped

Cancer, immunology, HIV research ensnared in fetal tissue politics

WHO recommends second malaria vaccine

Bring on the sabbaticals for nurses

knowledge

hotspot

leisure time

Supreme Court strikes down use of affirmative action

Congress extends some pandemic preparedness programs

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Asbestos ban is immediate, but health effects will linger for decades

Cancer drug shortages should be causing more outrage

Medicare innovation center doesn’t save money, experts say

After affirmative action ruling, medical educators look to 'holistic review'

Chinese researcher claims birth of first gene

Dobbs anniversary: the lost opportunity of abortion as health care

Setback for rare diseases as Taysha Gene Therapies pulls back

knowledge

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Chinese researcher claims birth of first gene

RSV injection headlines need to be accurate for good uptake

Setback for rare diseases as Taysha Gene Therapies pulls back

RSV injection headlines need to be accurate for good uptake

What Kate Middleton's cancer revelation might teach the world

knowledge

hotspot

entertainment

entertainment